Clinical Usefulness of Cancer Antigen (CA) 125, Human Epididymis 4, and CA72-4 Levels and Risk of Ovarian Malignancy Algorithm Values for Diagnosing Ovarian Tumors in Korean Patients With and Without Endometriosis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Tumor markers are useful for detection and preoperative evaluation of ovarian tumors. We evaluated the clinical usefulness of cancer antigen (CA) 125, human epididymis 4 (HE4), and CA72-4 levels and Risk of Ovarian Malignancy Algorithm (ROMA) values for differential diagnosis of malignant and borderline tumors among suspected ovarian tumors, and the effects of endometriosis on these tumor markers. Methods: In a total of 266 patients (213, 14, and 39 with benign, borderline and malignant tumors, respectively), CA125, HE4, and CA72-4 levels were measured, and ROMA values were calculated. Medians of each marker were compared among the three groups. The area under the ROC curve (AUC), sensitivity, and specificity were calculated to analyze the diagnostic performance of each marker. Results: All markers were significantly higher in the malignant group than in the benign group. HE4 levels and ROMA values were significantly higher in the malignant group than in the borderline group. ROMA value had the highest AUC for distinguishing the malignant and borderline groups from the benign group in premenopausal (0.773) and postmenopausal (0.927) patients. CA125 level was significantly higher in patients with endometriosis than in those without (P<0.001), whereas HE4 and CA72-4 levels were not affected by endometriosis (P=0.128 and 0.271, respectively). Conclusions: ROMA value is the best marker to distinguish malignant and borderline tumors from benign tumors in pre- and postmenopausal patients. HE4 and CA72-4 levels provide information on possible CA125 elevation due to endometriosis.
Abstract
Background: Tumor markers are useful for detection and preoperative evaluation of ovarian tumors. We evaluated the clinical usefulness of cancer antigen (CA) 125, human epididymis 4 (HE4), and CA72-4 levels and Risk of Ovarian Malignancy Algorithm (ROMA) values for differential diagnosis of malignant and borderline tumors among suspected ovarian tumors, and the effects of endometriosis on these tumor markers. Methods: In a total of 266 patients (213, 14, and 39 with benign, borderline and malignant tumors, respectively), CA125, HE4, and CA72-4 levels were measured, and ROMA values were calculated. Medians of each marker were compared among the three groups. The area under the ROC curve (AUC), sensitivity, and specificity were calculated to analyze the diagnostic performance of each marker. Results: All markers were significantly higher in the malignant group than in the benign group. HE4 levels and ROMA values were significantly higher in the malignant group than in the borderline group. ROMA value had the highest AUC for distinguishing the malignant and borderline groups from the benign group in premenopausal (0.773) and postmenopausal (0.927) patients. CA125 level was significantly higher in patients with endometriosis than in those without (P<0.001), whereas HE4 and CA72-4 levels were not affected by endometriosis (P=0.128 and 0.271, respectively). Conclusions: ROMA value is the best marker to distinguish malignant and borderline tumors from benign tumors in pre- and postmenopausal patients. HE4 and CA72-4 levels provide information on possible CA125 elevation due to endometriosis.
참고문헌 (29)
- Bray F, "Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 68, pp.394~424 (2018)
- Tchagang AB, "Early detection of ovarian cancer using group biomarkers", Mol Cancer Ther, 7, pp.27~37 (2008)
- Daly MB, "NCCN Guidelines Insights: genetic", familial high-risk assessment: breast and ovarian, version 2.2017, 2017, pp.15, 9~20
- Fotopoulou C, "British Gynaecological Cancer Society (BGCS) epithelial ovarian", Fallopian tube, Eur J Obstet Gynecol Reprod Biol, pp.2017, 213[DOI]
- Committee on Gynecologic Practice, "Committee Opinion No. 716. Committee Opinion No. 716: the role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer in women at average risk", Obstet Gynecol, 130, pp.e146~e149 (2017)
- Escudero JM, "Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases", Clin Chem, 57, pp.1534~1544 (2011)
- Aggarwal P, "Serum tumour markers in gynaecological cancers", Maturitas, 67, pp.46~53 (2010)
- Schummer M, "Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas", Gene, 238, pp.375~385 (1999)
- Guadagni F, "CA 72-4 serum marker—a new tool in the management of carcinoma patients", Cancer Invest, 13, pp.227~238 (1995)
- Lenhard MS, "Predictive value of CA 125 and CA 72-4 in ovarian borderline tumors", Clin Chem Lab Med, 47, pp.537~542 (2009)
- Granato T, "Role of HE4, CA72.4, and CA125 in monitoring ovarian cancer", Tumour Biol, 33, pp.1335~1339 (2012)
- Yang WL, "Elevation of TP53 autoantibody before CA125 in preclinical invasive epithelial ovarian cancer", Clin Cancer Res, 23, pp.5912~5922 (2017)
- Chudecka-Głaz AM, "ROMA, an algorithm for ovarian cancer", Clin Chim Acta, 440, pp.143~151 (2015)
- Jaime Prat, "FIGO’s staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication", Journal of Gynecologic Oncology, 26(2), pp.87~89 (2015), 대한부인종양학회
- Moore RG, "Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass", Obstet Gynecol, 118, pp.280~288 (2011)
- Ferraro S, "Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis : a systematic review", J Clin Pathol, 66, pp.273~281 (2013)
- Wang J, "Diagnostic accuracy of serum HE4, CA125 and ROMA in patients with ovarian cancer: a meta-analysis", Tumour Biol, 35, pp.6127~6138 (2014)
- Scaletta G, "The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review", Expert Rev Anticancer Ther, 17, pp.827~839 (2017)
- Moore RG, "A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass", Gynecol Oncol, 112, pp.40~46 (2009)
- Bandiera E, "Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian management", Cancer Epidemiol Biomark Prev, 20, pp.2496~2506 (2011)
- Ławicki S, "The plasma concentration of VEGF, HE4 and CA125 as a new biomarkers panel in different stages and sub-types of epithelial ovarian tumors", J Ovarian Res, 6, pp.45~ (2013)
- Van Gorp T, "HE4 and CA125 as a diagnostic test in ovarian cancer : prospective validation of the Risk of Ovarian Malignancy Algorithm", Br J Cancer, 104, pp.863~870 (2011)
- Moore RG, "Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders", Am J Obstet Gynecol, 206, pp.351.e1~351.e8 (2012)
- Anastasi E, "The use of HE4, CA125 and CA72-4 biomarkers for differential diagnosis between ovarian endometrioma and epithelial ovarian cancer", J Ovarian Res, 6, pp.44~ (2013)
- Nagy B Jr, "Elevated human epididymis protein 4 concentrations in chronic kidney disease", Ann Clin Biochem, 49, pp.377~380 (2012)
- Moore RG, "The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass", Gynecol Oncol, 108, pp.402~408 (2008)
- Jacob F, "No benefit from combining HE4 and CA 125 as ovarian tumor markers in a clinical setting", Gynecol Oncol, 121, pp.487~491 (2011)
- Chan KK, "The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass", Gynecol Oncol, 128, pp.239~244 (2013)
- Kadija S, "The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis", Int J Gynecol Cancer, 22, pp.238~244 (2012)